F
Replying to @Peptide Protocols
Buying an injectable from a bodega next to the rolling papers is wild, but I guarantee people did it because the packaging looked official and there was a COA online.
WIRED Lab-Tested Viral Bodega Peptides — 0/4 Vials Contained What Was on the Label
Started by Peptide Protocols•Bodega “peptides” just failed lab testing. WIRED bought them. None of the four vials contained the compound on the label.
WIRED reporters Sophie Kleeman and Kate Knibbs walked into Mr. Green, a bodega on Bedford Avenue in Brooklyn that had gone viral this summer for selling injectable peptides next to candy, gum, and rolling papers. For $376.20 they bought four INDR Labs vials: retatrutide, PT-141, BPC-157, and NAD+. The clerk put them in an unlabeled paper bag.
They sent the vials to Finnrick, an Austin firm that brokers independent peptide testing. Results:
Zero of the four vials contained the peptide listed on the label.
The BPC-157 had no BPC-157. The retatrutide had no retatrutide. Same for PT-141 and NAD+.
Endotoxin and heavy-metal levels were low. These were duds, not obviously toxic sludge.
WIRED’s story is here: Those Viral Bodega Peptides Aren’t Actually Peptides (Sep 15, 2026).
Klein’s read of the same data is the part worth sitting with: it is unclear whether this was bad storage, bad transport, or the product never containing the peptide at all. What is clear is that INDR Labs — the supplier behind the bodega stock — locked its site behind a login after WIRED started asking questions, and had already pulled public certificates of analysis. The company had claimed Vanguard Laboratory COAs. Vanguard has previously said it did not issue that paperwork.
This was not a one-shop fluke. Jeff Colhoun of Peptide Critic bought INDR Labs retatrutide and NAD+ from Smoker’s World, a smoke shop down the street from Mr. Green, and sent them to a different lab (Analytical Formulations). That lab could not positively identify the substances either.
Finnrick’s CEO pointed at the industrial pattern underneath the punchline: “turnkey” operations that let almost anyone slap a brand on product from the same weak upstream suppliers. Klein’s question is the right one: how many INDR-like companies are getting launched every day?
A few things this does not prove:
It does not prove every research-peptide vendor is fake.
It does not prove these particular vials were dangerous in the toxicology sense. The contaminant screens were relatively clean.
It does not prove the compounds “degraded in the bodega fridge.” Absence of the labeled peptide is also consistent with never having been there.
What it does prove is the thing the gray market keeps pretending is a rounding error: you cannot infer identity from a label, a COA screenshot, or a clerk in a paper bag. “Research use only” sold over a bodega counter is still an injectable you are trusting with your body. One woman already died this year after a peptide injection at an unlicensed Bronx spa. The FDA would not tell WIRED whether it has taken action against brick-and-mortar sellers like Mr. Green.
If you are buying peptides, the lesson is not “bodegas bad, internet vendors good.” The lesson is: independent identity testing is the product. Everything else is marketing.
Primary source: Sophie Kleeman and Kate Knibbs, WIRED, “Those Viral Bodega Peptides Aren’t Actually Peptides,” September 15, 2026.
